Open AccessAntiplatelet therapy in stroke prevention after non-cardioembolic transient ischemic attack
Author(s) -
A. V. Fonyakin,
Л.А. Гераскина,
M. Yu. Maksimova
Publication year - 2021
Publication title -
nevrologiâ, nejropsihiatriâ, psihosomatika
Language(s) - English
Resource type - Journals
eISSN - 2310-1342
pISSN - 2074-2711
DOI - 10.14412/2074-2711-2021-5-14-19
Subject(s) - clopidogrel , medicine , ischemic stroke , stroke (engine) , aspirin , secondary prevention , cardiology , randomized controlled trial , platelet aggregation inhibitor , minor stroke , ischemia , mechanical engineering , stenosis , engineering
The review shows modern concepts on the role of antiplatelet therapy in the secondary prevention of cardiovascular diseases in patients after non-cardioembolic ischemic stroke or transient ischemic attack (TIA). We present an analytical characteristic of all antiplatelet agents that have been studied in randomized controlled trials worldwide. We demonstrate the advantages and disadvantages of each agent in monotherapy and in combination. New ideas about the rationality of the use of combined antiplatelet therapy with clopidogrel and acetylsalicylic acid in the first 24 hours and no more than 90 days in patients with minor ischemic stroke or TIA are discussed. The efficacy and safety of new antiplatelet agents are analyzed. The basic principles of choosing antiplatelet agents in patients after ischemic noncardioembolic stroke/TIA are outlined.